Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- Biological: botulinum toxin Type A (200U)Other: Normal saline (Placebo); botulinum toxin Type A (300U)Biological: botulinum toxin Type A (300U)Other: Normal saline (Placebo); botulinum toxin Type A (200U)
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 275
- Registration Number
- NCT00461292
24-hour IOP-lowering Effect of Brimonidine 0.1%
Phase 4
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 15
- Registration Number
- NCT00457795
Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
Phase 2
Terminated
- Conditions
- Fibromyalgia
- Interventions
- Drug: AGN 203818Drug: placebo
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 211
- Registration Number
- NCT00445705
Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
Active, not recruiting
- Conditions
- Breast Implant
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 56460
- Registration Number
- NCT00443274
- Locations
- 🇺🇸
Southwest Plastic Surgery /ID# 240510, El Paso, Texas, United States
Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain
Phase 2
Terminated
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: AGN 203818Drug: placebo
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 213
- Registration Number
- NCT00441766
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
Phase 4
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2008-01-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT00440141
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
Phase 4
Completed
- Conditions
- Ocular HypertensionGlaucoma
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 266
- Registration Number
- NCT00440011
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Phase 3
Terminated
- Conditions
- Overactive Bladder
- Interventions
- Biological: botulinum toxin Type ADrug: Normal Saline (Placebo)
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 41
- Registration Number
- NCT00439140
Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia
Phase 4
Terminated
- Conditions
- Spasmodic Torticollis
- Interventions
- Biological: botulinum toxin type A
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 54
- Registration Number
- NCT00432341
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
Phase 2
Terminated
- Conditions
- Choroid NeovascularizationAge-Related Macular Degeneration
- Interventions
- Drug: AGN 211745Drug: Ranibizumab 500µg
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 138
- Registration Number
- NCT00395057
© Copyright 2025. All Rights Reserved by MedPath